Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;11(1):24-31.
doi: 10.1111/andr.13339. Epub 2022 Nov 28.

Androgen receptor polyQ alleles and COVID-19 severity in men: A replication study

Rosario López-Rodríguez  1   2   3 , Javier Ruiz-Hornillos  4 , Marta Cortón  1   2 , Berta Almoguera  1   2 , Pablo Minguez  1   2 , María Elena Pérez-Tomás  5 , María Barreda-Sánchez  5   6 , Esther Mancebo  7 , Lorena Ondo  1 , Andrea Martínez-Ramas  1 , Lidia Fernández-Caballero  1   2 , Juan Carlos Taracido-Fernández  8 , Antonio Herrero-González  8 , Ignacio Mahillo  9 ; STOP_Coronavirus Study Group  1 ; Estela Paz-Artal  7   10   11 , Encarna Guillén-Navarro  2   5 , Carmen Ayuso  1   2
Affiliations

Androgen receptor polyQ alleles and COVID-19 severity in men: A replication study

Rosario López-Rodríguez et al. Andrology. 2023 Jan.

Abstract

Background: Ample evidence indicates a sex-related difference in severity of COVID-19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity.

Objective: To test the association between the androgen receptor polyQ polymorphism and COVID-19 severity in a large cohort of COVID-19 male patients.

Materials and methods: This study included 1136 male patients infected with SARS-CoV-2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID-19 severity was assessed by Chi-squared (Chi2 ) and logistic regression analysis.

Results: The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis).

Discussion: Androgen sensitivity may be a critical factor in COVID-19 disease severity. However, we did not find an association between the polyQ polymorphism and the COVID-19 severity. Additional studies are needed to clarify the mechanism underlying the association between androgens and COVID-19 outcome.

Conclusions: The results obtained in our study do not support the role of this polymorphism as biomarker of COVID-19 severity.

Keywords: COVID-19; androgen receptor; biomarker; polyQ polymorphism; sex-related differences.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest

References

    1. Wray S, Arrowsmith S. The physiological mechanisms of the sex‐based difference in outcomes of COVID19 infection. Front Physiol. 2021;12:627260. 10.3389/fphys.2021.627260 - DOI - PMC - PubMed
    1. Viveiros A, Rasmuson J, Vu J, et al. Sex differences in COVID‐19: candidate pathways, genetics of ACE2, and sex hormones. Am J Physiol Circ Physiol. 2021;320(1):H296‐H304. 10.1152/ajpheart.00755.2020 - DOI - PMC - PubMed
    1. Fallerini C, Daga S, Mantovani S, et al. Association of toll‐like receptor 7 variants with life‐threatening COVID‐19 disease in males: findings from a nested case‐control study. Elife. 2021;10:e67569. 10.7554/eLife.67569 - DOI - PMC - PubMed
    1. van der Made CI, Simons A, Schuurs‐Hoeijmakers J, et al. Presence of genetic variants among young men with severe COVID‐19. JAMA. 2020;324(7):663‐673. 10.1001/jama.2020.13719 - DOI - PMC - PubMed
    1. Asano T, Boisson B, Onodi F, et al. X‐linked recessive TLR7 deficiency in ∼1% of men under 60 years old with life‐threatening COVID‐19. Sci Immunol. 2021;6(62):eabl4348. 10.1126/sciimmunol.abl4348 - DOI - PMC - PubMed

Publication types